This message contains images. If you don't see images, click here to view.
Click here to advertise in this news brief.

Mobile version  RSS  Subscribe  Unsubscribe  Archive  Media Kit |   AhHa B2B Search:     

Home   About AST   Education   Meetings & Events   Public Policy   Contact Us   Nov. 8, 2012


Role of age and EBV status on PTLD incidence among pediatric heart transplant recipients
American Journal of Transplantation    Share    Share on FacebookTwitterShare on LinkedinE-mail article
The objective of a recent study was to determine the incidence and hazard for posttransplant lymphoproliferative disease (PTLD) in a study of 3170 pediatric primary heart transplants between 1993 and 2009 at 35 institutions in the Pediatric Heart Transplant Study. Findings indicate that EBV status and the age of the recipient at the time of transplantation are important variables in the development of PTLD in the pediatric heart transplant recipient. More

Iso-Tex Diagnostics, Inc.

• We are an FDA licensed manufacturer.
• We label peptides, monoclonal antibodies, reagents, chemical   and proteins for cancer treatments.
• Our above products can be labeled with radioisotopes such as   I-125, I-131, P32, Tc99m, Y90 and AC-225.
• We have a multicurie isotope license and an animal facility.

Is your center participating in the Institutional Support Program?
AST    Share    Share on FacebookTwitterShare on LinkedinE-mail article
AST's new institutional support program provides transplant centers with year-round recognition, access to the AST membership and a number of tangible benefits. Members who are interested in obtaining greater exposure for their transplant program are encouraged to consider having their center participate. For more information click here.

C1qScreen™: A New Research Tool for AMR Risk
Identify Antibodies That May Compromise Graft Survival
  • Detect Presence of Complement Fixing Antibodies
  • Investigate risk of developing Antibody Mediated Rejection (AMR)
Request a Complimentary Sample Kit!

For Research Use Only. Not for use in diagnostic procedures.

Business of Transplantation live monthly webinar series
AST    Share    Share on FacebookTwitterShare on LinkedinE-mail article
AST's Transplant Administrators Community of Practice introduces a live webinar series on the second Wednesday of each month from November 2012 to June 2013. The webinar is free for AST members, and $50 per session for non-members. These webinars are designed for anyone seeking instruction in the business side of transplantation, particularly staff in leadership positions. Participants will gain knowledge and skills to develop and implement robust transplant quality assurance programs and valuable insight about the extremely complex transplant regulatory and financial framework. Read more and pre-register today!

Register now for AST's Cutting Edge of Transplantation and save 50 percent
AST    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Registration is open for AST's Cutting Edge of Transplantation meeting taking place Feb. 14-16, 2013 at the Sheraton Wild Horse Pass near Scottsdale, Ariz. Register by Nov. 30 and receive 50 percent off of regular registration rates. The program features experts from basic, translational and clinical science, and tackles questions and challenges surrounding antibodies. Read more about the science and register today!

AST Fellows Symposium 2012 slides with audio available
AST    Share    Share on FacebookTwitterShare on LinkedinE-mail article
View full speaker slide presentations with synchronized audio from the 2012 AST Fellows Symposium on Transplantation Medicine. The videos are free for AST members; non-members may purchase access for $149. Log in or purchase on the AST Education web page in the Fellows section.The Fellows Symposium is designed for clinical fellows and residents, surgical fellows, research fellows, pharmacists, non-doctoral allied health professionals and other trainees who are planning a career in transplantation medicine, surgery, or research. Learn about the field of solid organ transplantation from experts in both basic science and clinical care.

Athena Diagnostics

Genetic testing can be a cost-effective way to increase the number of living related donor transplants. Mutational analysis may help direct long-term treatment plans, including pre-operative screening of potential kidney transplant recipients and living related donors.
WAVES by Waters Medical Systems
✓ Hypothermic preservation of a single kidney using physiologic pulsatile preservation and membrane oxygenation: a proven technology from Waters Medical Systems (more than 40 years clinical experience) ✓ Simplifies the perfusion process (provides more options to view, chart, and trend data, offers web-based remote monitoring, and a transportable design)
✓ Meets or exceeds current FDA standards and AOPO and UNOS Preservation Guidelines.
MNX: Organ Transportation
When it comes to saving lives, MNX understands organ transplant logistics. Every shipment is urgent, and every step critical. That’s why MNX offers specialty services that are tailored for organ transportation. From expedited ground service to charter flights, MNX has the proven experience and operational resources you can count on.


Progressive graft fibrosis and donor-specific human leukocyte antigen antibodies in pediatric late liver allografts
Liver Transplantation (subscription required)    Share    Share on FacebookTwitterShare on LinkedinE-mail article
The role of donor-specific anti-human leukocyte antigen antibodies (DSAs) that develop late after living donor liver transplantation is unknown. Seventy-nine pediatric recipients who had good graft function and underwent protocol liver biopsy more than 5 years after transplantation (median = 11 years, range = 5-20 years) were reviewed. The donor specificity of antibodies could be identified in 67 patients: DSAs were detected in 32 patients (48 percent), and they were usually against human leukocyte antigen class II (30 cases) but were rarely against class I (2 cases). The high prevalence of graft fibrosis and anti–class II DSAs in late protocol biopsy samples suggests that humoral alloreactivity may contribute to the process of unexplained graft fibrosis late after liver transplantation. More

Plasma adiponectin before and after kidney transplantation
Transplant International (subscription required)    Share    Share on FacebookTwitterShare on LinkedinE-mail article
The role of plasma adiponectin (ADPN) in patients with impaired kidney function and following kidney transplantation (Tx) is debated. Several factors determine the ADPN concentration before and after Tx including kidney function, insulin resistance, use of immunosuppressive agents and BMI. In a recent study, researchers concluded pretransplant ADPN level did not predict development of new-onset diabetes mellitus or even deterioration of the glucose tolerance following Tx. More

Long-term outcomes of living donor kidney transplants in pediatric recipients following laparoscopic vs. open donor nephrectomy
Pediatric Transplantation (subscription required)    Share    Share on FacebookTwitterShare on LinkedinE-mail article
A recent study compared long-term outcomes of LDKT in pediatric recipients following either laparoscopic (LDN) or ODN. In a retrospective single-center study, researchers compared 38 pediatric LDKT recipients of a laparoscopically procured kidney with a historic ODN group comprising 17 pediatric recipients. In the center, the first pure laparoscopic non-hand-assisted LDN for a pediatric LDKT recipient was performed in June 2001. Arterial multiplicity was associated with a higher incidence of DGF. More

Predictors of early graft loss confirmed
Renal & Urology News    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Researchers who studied pairs of renal transplant recipients who received kidneys from the same donor have confirmed previously identified recipient risk factors for early renal graft loss, according to a report presented at Kidney Week 2012. More

Effects of 2 mesenchymal cell populations on hepatocytes and lymphocytes
Liver Transplantation (subscription required)    Share    Share on FacebookTwitterShare on LinkedinE-mail article
The inflammatory response to liver injury plays an important role in the onset of liver fibrosis, which may ultimately lead to liver failure. The attenuation of inflammation and hepatocyte rescue are, therefore, of the utmost importance for recovery. Mesenchymal stromal cells (MSCs) from adult bone marrow have been shown to rescue hepatocyte function. In a recent study, researchers explored a more plentiful source of neonatal MSCs: Human umbilical cord perivascular cells (HUCPVCs). More

Association of mycophenolic acid dose with efficacy and safety events in kidney transplant patients receiving tacrolimus
Clinical Transplantation    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Dose-finding studies for mycophenolic acid (MPA) in tacrolimus-treated kidney transplant patients are lacking. Data from 901 de novo kidney transplant recipients enrolled in the prospective, non-interventional Mycophenolic acid Observational REnal (MORE) transplant registry were analyzed according to baseline daily MPA dose (less than 2000, 2000 or more than 2000 mg). Findings suggest that an initial MPA dose of less than 2000 mg does not compromise 12-month efficacy in tacrolimus-treated kidney transplants, but controlled trials are required and the lower threshold for MPA dose remains to be defined. More

PPI use with MMF may increase acute rejection risk
Renal & Urology News    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Renal transplant recipients who use of proton pump inhibitors (PPIs) and mycophenolate mofetil (MMF) in the first year after transplantation may be at increased risk for allograft acute rejection, data presented at Kidney Week 2012 suggest. More

Terlipressin in brain death donors
Clinical Transplantation (subscription required)    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Metabolic management of brain death organ donors includes correction of the hormonal perturbations that occur after cerebral death and impair circulatory function. A recent review of pharmacology and literature about the use of terlipressin in shock, particularly neurogenic shock following brain death, found that terlipressin is helpful in controlling severe hypotension. More

Coronary artery disease increases mortality, cardiovascular event risk in liver transplant recipients
Healio    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Patients with coronary artery disease who undergo liver transplantation are at increased risk for cardiovascular events and death following the procedure, according to data presented at the 2012 American College of Gastroenterology Annual Scientific Meeting. More

AST eNews

Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Courtney Hodges, Content Editor, 972.402.2604   
Contribute news

This edition of the AST eNews was sent to ##Email##. To unsubscribe, click here.

Recent issues
Nov. 1, 2012
Oct. 25, 2012
Oct. 18, 2012
Oct. 11, 2012

7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063